PAM
IONS icon

Paradigm Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Paradigm Asset Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,100
Closed -$56K – 456
2017
Q2 		$56K Sell
1,100
-1,100
-50% -$51.2K 0.01% 513
2017
Q1 		$88.4K Sell
2,200
-7,100
-76% -$319K 0.02% 538
2016
Q4 		$445K Sell
9,300
-300
-3% -$11.9K 0.09% 211
2016
Q3 		$352K Sell
9,600
-2,000
-17% -$62.6K 0.06% 284
2016
Q2 		$270K Sell
11,600
-600
-5% -$19.4K 0.05% 293
2016
Q1 		$494K Hold
12,200
– – 0.09% 221
2015
Q4 		$756K Sell
12,200
-62,300
-84% -$3.36M 0.13% 144
2015
Q3 		$3.01M Buy
+74,500
New +$3.86M 0.39% 82
2015
Q1 		– Sell
-69,050
Closed -$4.26M – 814
2014
Q4 		$4.26M Sell
69,050
-28,400
-29% -$1.4M 0.55% 63
2014
Q3 		$3.78M Buy
97,450
+81,600
+515% +$2.89M 0.53% 66
2014
Q2 		$546K Sell
15,850
-13,700
-46% -$431K 0.07% 300
2014
Q1 		$1.28M Sell
29,550
-2,300
-7% -$111K 0.17% 163
2013
Q4 		$1.27M Sell
31,850
-800
-2% -$28.5K 0.19% 167
2013
Q3 		$1.23M Sell
32,650
-1,500
-4% -$44.8K 0.2% 149
2013
Q2 		$918K Buy
+34,150
New +$726K 0.16% 182

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Paradigm Asset Management's IONS Position: Q3 2017 in Review

Paradigm Asset Management sold out of Ionis Pharmaceuticals (IONS) in Q3 2017, closing a stake of 1,100 shares — an estimated $56K sold.

Paradigm Asset Management first reported a position in IONS in Q2 2013 and held it in 15 quarters. The position peaked at $4.26M in Q4 2014. 301 funds tracked by Wall St. Rank hold IONS as of Q3 2017.

  • Paradigm Asset Management reported no remaining Ionis Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Paradigm Asset Management sold 1,100 Ionis Pharmaceuticals shares in Q3 2017, an estimated $56K.
  • Paradigm Asset Management first reported a position in Ionis Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • Paradigm Asset Management's Ionis Pharmaceuticals position peaked at $4.26M in Q4 2014.
  • 301 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2017.

Based on Paradigm Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.